Physician profile
Laura Johnson
NPI 1922890474
$899.59
in general payments reported to CMS, 2019-2025
14 companies · $884 in 2025
The $884 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $15.48 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.58 | 2024-2025 | |
| Madrigal Pharmaceuticals | $109.80 | 2025 | Rezdiffra |
| Celltrion USA INC. | $103.61 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $76.70 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $64.24 | 2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $63.12 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $58.60 | 2025 | Dupixent |
| Novo Nordisk INC | $27.80 | 2025 | Wegovy |
| Gilead Sciences, INC. | $26.18 | 2025 | |
| Qol Medical, LLC | $25.37 | 2025 | Sucraid |
| Ardelyx, INC. | $23.91 | 2025 | Ibsrela |
| Lilly USA, LLC | $22.08 | 2025 | Omvoh |
| Genzyme Corporation | $21.73 | 2025 | |
| Evoke Pharma, INC. | $15.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.